Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating oral Nizubaglustat (AZ-3102) for late-infantile and juvenile GM1 gangliosidosis and GM2 gangliosidosis, and the study is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gm1 Gangliosidosis
• Gm2 Gangliosidosis

Drugs mentioned

• Nizubaglustat

Snippet

Sponsor: Azafaros A.G. | Conditions: Gangliosidoses, GM2, Gangliosidosis, GM1 | Phase 3 | Status: RECRUITING